These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35597386)
1. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia. Sanabria BD; Palmegiani E; Seron AF; Perdomo YC; Miot HA; Müller Ramos P J Am Acad Dermatol; 2023 Feb; 88(2):436-437. PubMed ID: 35597386 [No Abstract] [Full Text] [Related]
2. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. Jimenez-Cauhe J; Saceda-Corralo D; Hermosa-Gelbard A; Moreno-Arrones OM; Pindado-Ortega C; de Dios Berna-Rico E; Ortega-Quijano D; Fernandez-Nieto D; Vaño-Galvan S J Am Acad Dermatol; 2022 Dec; 87(6):e235-e237. PubMed ID: 35973597 [No Abstract] [Full Text] [Related]
3. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712 [TBL] [Abstract][Full Text] [Related]
4. Minoxidil in the treatment of androgenetic alopecia. Goren A; Naccarato T Dermatol Ther; 2018 Sep; 31(5):e12686. PubMed ID: 30155952 [TBL] [Abstract][Full Text] [Related]
5. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Gassmueller J; Hoffmann R; Webster A Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309 [TBL] [Abstract][Full Text] [Related]
6. Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia. Gupta AK; Charrette A Skinmed; 2015; 13(3):185-9. PubMed ID: 26380504 [TBL] [Abstract][Full Text] [Related]
7. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Hoedemaker C; van Egmond S; Sinclair R Australas J Dermatol; 2007 Feb; 48(1):43-5. PubMed ID: 17222303 [TBL] [Abstract][Full Text] [Related]
8. Guidelines for the management of androgenetic alopecia (2010). Tsuboi R; Itami S; Inui S; Ueki R; Katsuoka K; Kurata S; Kono T; Saito N; Manabe M; Yamazaki M; J Dermatol; 2012 Feb; 39(2):113-20. PubMed ID: 22171995 [No Abstract] [Full Text] [Related]
9. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Walsh DS; Dunn CL; James WD Arch Dermatol; 1995 Dec; 131(12):1373-5. PubMed ID: 7492124 [No Abstract] [Full Text] [Related]
10. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764 [TBL] [Abstract][Full Text] [Related]
11. Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Saraswat A; Kumar B Arch Dermatol; 2003 Sep; 139(9):1219-21. PubMed ID: 12975174 [No Abstract] [Full Text] [Related]
12. Oral minoxidil 7.5 mg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring. Sanabria BD; Perdomo YC; Miot HA; Ramos PM An Bras Dermatol; 2024; 99(5):734-736. PubMed ID: 38772752 [No Abstract] [Full Text] [Related]
13. The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review. Sung CT; Juhasz ML; Choi FD; Mesinkovska NA J Drugs Dermatol; 2019 Feb; 18(2):155-160. PubMed ID: 30794366 [TBL] [Abstract][Full Text] [Related]
14. Controversies in the treatment of androgenetic alopecia: The history of finasteride. Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001 [TBL] [Abstract][Full Text] [Related]
15. Common hair loss disorders. Springer K; Brown M; Stulberg DL Am Fam Physician; 2003 Jul; 68(1):93-102. PubMed ID: 12887115 [TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. Tsuboi R; Arano O; Nishikawa T; Yamada H; Katsuoka K J Dermatol; 2009 Aug; 36(8):437-46. PubMed ID: 19691748 [TBL] [Abstract][Full Text] [Related]
17. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study. Ong M; Do H; Ho B; Lipner SR J Am Acad Dermatol; 2024 Feb; 90(2):425-427. PubMed ID: 37839733 [No Abstract] [Full Text] [Related]
18. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. Abdel-Raouf H; Aly UF; Medhat W; Ahmed SS; Abdel-Aziz RTA Dermatol Ther; 2021 Jan; 34(1):e14678. PubMed ID: 33320406 [TBL] [Abstract][Full Text] [Related]
19. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. Dhurat R; Chitallia J; May TW; Jayaraaman AM; Madhukara J; Anandan S; Vaidya P; Klenk A Skin Pharmacol Physiol; 2017; 30(6):298-305. PubMed ID: 29055953 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. Faghihi G; Mozafarpoor S; Asilian A; Mokhtari F; Esfahani AA; Bafandeh B; Nouraei S; Nilforoushzadeh MA; Hosseini SM Indian J Dermatol Venereol Leprol; 2018; 84(5):547-553. PubMed ID: 30027912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]